Rishabh Jain, Medical Consultant at Renova Hospital (RHL), shared a post on X:
“Can immunotherapy before surgery change the future of resectable HCC?
PRIME-HCC | Phase Ib | Lancet Oncology 2026
33 patients received neoadjuvant nivolumab + ipilimumab.
Key results:
- 22% complete pathological response (6/27)
- 33% major pathological response (≥70%)
- 91% underwent surgery • 9% grade 3 treatment-related AEs
The ctDNA signal is particularly interesting!
2-year recurrence-free survival:
- ctDNA undetectable: 82%
- ctDNA detectable: 29% (p=0.049)
Verdict: Neoadjuvant dual checkpoint blockade appears feasible in selected resectable HCC. ctDNA may help identify recurrence risk, but these exploratory findings need validation.
Small, single-arm study. Not practice-changing yet.”
Title: Neoadjuvant nivolumab plus ipilimumab in surgically resectable hepatocellular carcinoma (PRIME-HCC): a prospective, phase 1b, single-arm trial and translational analyses
Authors: Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Madhava Pai, Alexandra Emilia Schlaak, Duncan Spalding, Ira Godbole, Robert D Goldin, Nicole Acuti, Caroline Ward, Georgios Nteliopoulos, Vincent Yip, Sarah Slater, Poyyamozhi Rajagopal, Mikael Sodergren, Paul Tait, Nagy Habib, Robert Thomas, Eslam Maher, Francesco A Mauri, Alessio Cortellini, Julian R Marchesi, Bertram Bengsch, Rohini Sharma, David James Pinato
Read the Full Article on The Lancet Oncology

You can also read: Nivolumab With deb-TACE in Liver-Limited Hepatocellular Carcinoma
